Research progress of in-situ gelling ophthalmic drug delivery system
|
摘要
Blindness and vision impairment are the most devastating global health problems resulting in a substantial economic and social burden. Delivery of drug to particular parts of the anterior or posterior segment has been a major challenge due to various protective barriers and elimination mechanisms associated with the unique anatomical and physiological nature of the ocular system. Drug administration to the eye by conventional delivery systems results in poor ocular bioavailability( < 5%). The designing of a novel approach for a safe, simple, and effective ocular drug delivery is a major concern and requires innovative strategies to combat the problem. Over the past decades, several novel approaches involving different strategies have been developed to improve the ocular delivery system. Among these, the ophthalmic in-situ gel has attained a great attention over the past few years. This review discussed and summarized the recent and the promising research progress of in-situ gelling in ocular drug delivery system.
Blindness and vision impairment are the most devastating global health problems resulting in a substantial economic and social burden. Delivery of drug to particular parts of the anterior or posterior segment has been a major challenge due to various protective barriers and elimination mechanisms associated with the unique anatomical and physiological nature of the ocular system. Drug administration to the eye by conventional delivery systems results in poor ocular bioavailability( < 5%). The designing of a novel approach for a safe, simple, and effective ocular drug delivery is a major concern and requires innovative strategies to combat the problem. Over the past decades, several novel approaches involving different strategies have been developed to improve the ocular delivery system. Among these, the ophthalmic in-situ gel has attained a great attention over the past few years. This review discussed and summarized the recent and the promising research progress of in-situ gelling in ocular drug delivery system.
Blindness and vision impairment are the most devastating global health problems resulting in a substantial economic and social burden. Delivery of drug to particular parts of the anterior or posterior segment has been a major challenge due to various protective barriers and elimination mechanisms associated with the unique anatomical and physiological nature of the ocular system. Drug administration to the eye by conventional delivery systems results in poor ocular bioavailability( < 5%). The designing of a novel approach for a safe, simple, and effective ocular drug delivery is a major concern and requires innovative strategies to combat the problem. Over the past decades, several novel approaches involving different strategies have been developed to improve the ocular delivery system. Among these, the ophthalmic in-situ gel has attained a great attention over the past few years. This review discussed and summarized the recent and the promising research progress of in-situ gelling in ocular drug delivery system.
引文
[1]Addo E,Bamiro OA,Siwale R.Anatomy of the eye and common diseases affecting the eye.In:Addo RT,editor.Ocular drug delivery:Advances,challenges and applications.;2016.p.11-25.
[2]Joseph RR,Venkatraman SS.Drug delivery to the eye:what benefits do nanocarriers offer.Nanomedicine(Lond)2017;12(6):683-702.
[3]Zhu M,Wang J,Li N.A novel thermo-sensitive hydrogel-based on poly(N-isopropylacrylamide)/hyaluronic acid of ketoconazole for ophthalmic delivery.Artif Cells Nanomed Biotechnol 2017.doi:10.1080/21691401.2017.1368024.
[4]Bisht R,Mandal A,Jaiswal JK,Rupenthal ID.Nanocarrier mediated retinal drug delivery:overcoming ocular barriers to treat posterior eye diseases.WIREs Nanomed Nanobiotechnol 2018.doi:10.1002/wnan.1473.
[5]Makwana SB,Patel VA,Parmar SJ.Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride.Results Pharma Sci2016;6:1-6.
[6]Kaur IP,Smitha R.Penetration enhancers and ocular bioadhesives:two new avenues for ophthalmic drug delivery.Drug Dev Ind Pharm 2002;28(4):353-69.
[7]Bamiro OA,Ubale RV,Addo RT.Background of Ocular Drug Delivery.In:Addo RT,editor.Ocular drug delivery:Advances,challenges and applications.Springer International Publishing;2016.p.1-9.
[8]Kotreka UK,Davis VL,Adeyeye MC.Development of topical ophthalmic in situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts.PLoSOne 2017;12(2):e0172306.
[9]Ye T,Yuan K,Zhang W,et al.Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery.Asian J Pharmaceut Sci 2013;8(4):207-17.
[10]Liu Y,Liu J,Zhang X,Zhang R,Huang Y,Wu C.In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery.AAPS PharmSciTech 2010;11(2):610-20.
[11]Tan G,Yu S,Pan H,et al.Bioadhesive chitosan-loaded liposomes:a more efficient and higher permeable ocular delivery platform for timolol maleate.Int J Biol Macromol2017;94(Pt A):355-63.
[12]Addo RT,Yeboah KG,Siwale RC,et al.Formulation and characterization of atropine sulfate in albumin-chitosan microparticles for in vivo ocular drug delivery.J Pharm Sci2015;104(5):1677-90.
[13]Biswas GR,Majee SB.Niosomes in ocular drug delivery.Eur JPharmaceut Med Res 2017;4(7):813-19.
[14]Prausnitz MR,Jiang J,Pate SR,et al..In:Ocular drug delivery using microneedles;2007.p.3191.
[15]Duan Y,Cai X,Du H,Zhai G.Novel in situ gel systems based on P123/TPGS mixed micelles and gellan gum for ophthalmic delivery of curcumin.Colloids Surf BBiointerfaces 2015;128:322-30.
[16]Malavade S.Overview of the ophthalmic system.In:Pathak Y,Sutariya V,Hirani AA,editors.Nano-Biomaterials for ophthalmic drug delivery.Springer International Publishing;2016.p.9-35.
[17]Almeida H,Amaral MH,Lobao P,Lobo JM.In situ gelling systems:a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations.Drug Discov Today 2014;19(4):400-12.
[18]Weng Y,Liu J,Jin S,Guo W,Liang X,Hu Z.Nanotechnology-based strategies for treatment of ocular disease.Acta Pharm Sin B 2017;7(3):281-91.
[19]Huang D,Chen YS,Rupenthal ID.Overcoming ocular drug delivery barriers through the use of physical forces.Adv Drug Deliv Rev 2017.doi:10.1016/j.addr.2017.09.008.
[20]Achouri D,Alhanout K,Piccerelle P,Andrieu V.Recent advances in ocular drug delivery.Drug Dev Ind Pharm2013;39(11):1599-617.
[21]Khan N,Aqil M,Imam SS,Ali A.Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery:in vitro and ex vivo characterization.Pharm Dev Technol 2015;20(6):662-9.
[22]Li J,Zhao H,Okeke CI,et al.Comparison of systemic absorption between ofloxacin ophthalmic in situ gels and ofloxacin conventional ophthalmic solutions administration to rabbit eyes by HPLC-MS/MS.Int J Pharm2013;450(1-2):104-13.
[23]Devasani SR,Dev A,Rathod S,Deshmukh G.An overview of in situ gelling systems.Pharmaceut Biolog Evaluat2016;3(1):60-9.
[24]Cao Y,Zhang C,Shen W,Cheng Z,Yu LL,Ping Q.Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.J Control Release 2007;120(3):186-94.
[25]Sheshala R,Kok YY,Ng JM,Thakur RR,Dua K.In situ gelling ophthalmic drug delivery system:an overview and its applications.Recent Pat Drug Deliv Formul 2015;9(3):237-48.
[26]Laddha UD,Mahajan HS.An insight to ocular in situ gelling systems.Int J Adv Pharmaceut 2017;06(02):31-40.
[27]Wei G,Xu H,Ding PT,Li SM,Zheng JM.Thermosetting gels with modulated gelation temperature for ophthalmic use:the rheological and gamma scintigraphic studies.J Control Release 2002;83(1):65-74.
[28]Patel N,Nakrani H,Raval M,Navin S.Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.Drug Deliv 2016;23(9):3712-23.
[29]Klouda L.Thermoresponsive hydrogels in biomedical applications:a seven-year update.Eur J Pharm Biopharm2015;97(Pt B):338-49.
[30]Almeida H,Amaral MH,Lobao P.Temperature and p Hstimuli-responsive polymers and their applications in controlled and selfregulated drug delivery.J App Pharm Sci2012;2(6):1-10.
[31]Almeida H,Amaral MH,Lobao P,Sousa Lobo JM.Applications of poloxamers in ophthalmic pharmaceutical formulations:an overview.Expert Opin Drug Deliv2013;10(9):1223-37.
[32]Escobar-Chavez JJ,Lopez-Cervantes M,Naik A,Kalia YN,Quintanar-Guerrero D,Ganem-Quintanar A.Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations.J Pharm Pharm Sci 2006;9(3):339-58.
[33]Miyazaki S,Suzuki S,Kawasaki N,Endo K,Takahashi A,Attwood D.In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride.Int J Pharm 2001;229(1):29-36.
[34]Zambito Y,Colo GD.Polysaccharides as excipients for ocular topical formulations.Polysaccharides as excipients for ocular topical formulations.In Tech;2011.p.253-80.
[35]Rajoria G,Gupta A.In-situ gelling system:a novel approach for ocular drug delivery.Am J PharmTech Res2012;2(4):24-53.
[36]Pal K,Paulson AT,Rousseau D.Biopolymers in controlled-release delivery systems.In:Ebnesajjad S,editor.Handbook of biopolymers and biodegradable plastics properties,processing,and applications.Elsevier;2013.p.347-8.
[37]Mohammed S,Chouhan G,Anuforom O,et al.Thermosensitive hydrogel as an in situ gelling antimicrobial ocular dressing.Mater Sci Eng C Mater Biol Appl 2017;78:203-9.
[38]Liu L,Gao Q,Lu X,Zhou H.In situ forming hydrogels based on chitosan for drug delivery and tissue regeneration.Asian J Pharmaceut Sci 2016;11(6):673-83.
[39]Chen X,Li X,Zhou Y,et al.Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system:preparation,characterization,and in vivo evaluation.JBiomater Appl 2012;27(4):391-402.
[40]Shastri DH.Thiolated chitosan:a boon to ocular delivery of therapeutics.MOJ Bioequiv Availab 2017;3(2):1-5.
[41]Li J,Liu H,Liu LL,Cai CN,Xin HX,Liu W.Design and evaluation of a Brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery.Chem Pharm Bull(Tokyo)2014;62(10):1000-1008.
[42]Al-Khateb K,Ozhmukhametova EK,Mussin MN,et al.In situ gelling systems based on Pluronic F127/Pluronic F68formulations for ocular drug delivery.Int J Pharm2016;502(1-2):70-9.
[43]Osswald CR,Guthrie MJ,Avila A,Valio JJ,Mieler WF,Kang-Mieler JJ.In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system.Curr Eye Res 2017;42(9):1293-301.
[44]Vodithala S,Khatry S,Shastri N,Sadanandam M.Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine.Int J Biopharm2010;1(1):39-45.
[45]Morsi N,Ghorab D,Refai H,Teba H.Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery.Int J Pharm 2016;506(1-2):57-67.
[46]Bhowmik M,Bain MK,Ghosh LK,Chattopadhyay D.Effect of salts on gelation and drug release profiles of methylcellulose-based ophthalmic thermo-reversible in situ gels.Pharm Dev Technol 2011;16(4):385-91.
[47]Bhowmick B,Sarkar G,Roy I,et al.Effect of carrageenan and potassium chloride on in-situ gelling ophthalmic drug delivery system based on methylcellulose.Rsc Adv2015;5(74):60386-91.
[48]Gratieri T,Gelfuso GM,Rocha EM,Sarmento VH,de-Freitas O,Lopez RF.A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery.Eur J Pharm Biopharm 2010;75(2):186-93.
[49]Hsiue GH,Hsu SH,Yang CC,Lee SH,Yang IK.Preparation of controlled release ophthalmic drops,for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide.Biomaterials 2002;23(2):457-62.
[50]Iohara D,Okubo M,Anraku M,et al.Hydrophobically modified polymer/α-cyclodextrin thermoresponsive hydrogels for use in ocular drug delivery.Mol Pharm2017;14(8):2740-8.
[51]Sawant D,Dandagi PM,Gadad AP.Formulation and evaluation of sparfloxacin emulsomes-loaded thermosensitive in situ gel for ophthalmic delivery.JSol-Gel Sci Technol 2016;77(3):654-65.
[52]Wang L,Che X,Guo Y,Bian Y,Cheng G.Thermoresponsive ophthalmic poloxamer/tween/carbopol in situ gels of a poorly water-soluble drug fluconazole:preparation and in vitro-in vivo evaluation.Drug Dev Ind Pharm2014;40(10):1402-10.
[53]Gadad AP,Wadklar PD,Dandghi P,Patil A.Thermosensitive in situ gel for ocular delivery of lomefloxacin.Ind JPharmaceut Educ Res 2016;50(2):S96-105.
[54]Qian Y,Wang F,Li R,Zhang Q,Xu Q.Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide.Drug Dev Ind Pharm2010;36(11):1340-7.
[55]Asasutjarit R,Thanasanchokpibull S,Fuongfuchat A,Veeranondha S.Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels.Int J Pharm 2011;411(1-2):128-35.
[56]Ammar HO,Salama HA,Ghorab M,Mahmoud AA.Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery.Drug Dev Ind Pharm2010;36(11):1330-9.
[57]Lin HR,Sung KC.Carbopol/pluronic phase change solutions for ophthalmic drug delivery.J Control Release2000;69(3):379-88.
[58]Wu H,Liu Z,Peng J,Li L,Li N,Li J.Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery.Int J Pharm2011;410(1-2):31-40.
[59]Pang X,Li J,Pi J,et al.Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits.Pharm Dev Technol 2018;23(3):231-9.
[60]Upadhayay P,Kumar M,Pathak K.Norfloxacin loaded p Htriggered nanoparticulate in-situ gel for extraocular bacterial infections:optimization,ocular irritancy and corneal toxicity.Iran J Pharm Res 2016;15(1):3-22.
[61]Gupta S,Vyas SP.Carbopol/chitosan based p H triggered in situ gelling system for ocular delivery of timolol maleate.Sci Pharm 2010;78(4):959-76.
[62]Kanoujia J,Sonker K,Pandey M,Kymonil KM,Saraf SA.Formulation and characterization of a novel pH-triggered in-situ gelling ocular system containing Gatifloxacin.Int Current Pharmaceut J 2012;1(3):43-9.
[63]Sheikh AA,Sheikh SR,Admane SS.Development and characterization of novel in situ gel of moxifloxacin hydrochloride.Asian J.Pharm.2017;11(3):S616-24.
[64]Rupenthal ID,Green CR,Alany RG.Comparison of ion-activated in situ gelling systems for ocular drug delivery.part 2:precorneal retention and in vivo pharmacodynamic study.Int J Pharm 2011;411(1-2):78-85.
[65]Agrawal AK,Das M,Jain S.In situ gel systems as’smart’carriers for sustained ocular drug delivery.Expert Opin Drug Deliv 2012;9(4):383-402.
[66]Fernandez-Ferreiro A,Fernandez Bargiela N,Varela MS,et al.Cyclodextrin-polysaccharide-based,in situ-gelled system for ocular antifungal delivery.Beilstein J Org Chem2014;10:2903-11.
[67]Reed K,Li A,Wilson B,Assamoi T.Enhancement of ocular in situ gelling properties of low acyl gellan gum by use of ion exchange.J Ocul Pharmacol Ther 2016;32(9):574-82.
[68]Champalal KD,Sushilkumar SP.Current status of ophthalmic in-situ forming hydrogel.Int J Pharma Bio Sci2012;3(3):P372-88.
[69]Mishra DN,Gilhotra RM.Design and characterization of bioadhesive in-situ gelling ocular inserts of Gatifloxacin sesquihydrate.DARU:J Pharmaceut Sci 2008;16(1):1-8.
[70]Nirmal HB,Bakliwal SR,Pawar SP.In-situ gel:new trends in controlled and sustained drug delivery system.Int JPharmTech Res 2010;2(2):1398-408.
[71]Vijaya C,Goud KS.Ion-activated in situ gelling ophthalmic delivery systems of Azithromycin.Indian J of Pharm Sci2011;73(6):615-20.
[72]Zhu L,Ao J,Li P.A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen:in vitro and in vivo evaluation.Drug Des Devel Ther 2015;9:3943-9.
[73]Kesarla R,Tank T,Vora PA,Shah T,Parmar S,Omri A.Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel.Drug Deliv 2016;23(7):2363-70.
[74]Tayel SA,El-Nabarawi MA,Tadros MI,Abd-Elsalam WH.Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride:design,in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits.Int JPharm 2013;443(1-2):293-305.
[75]Liu Z,Li J,Nie S,Liu H,Ding P,Pan W.Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin.Int J Pharm 2006;315(1-2):12-17.
[76]Liu Z,Yang XG,Li X,Pan W,Li J.Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis.Drug Dev Ind Pharm 2007;33(12):1327-31.
[77]Morsi N,Ibrahim M,Refai H,El Sorogy H.Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide.Eur J Pharm Sci2017;104:302-14.
[78]Rupenthal ID,Alany RG,Green CR.Ion-activated in situ gelling systems for antisense oligodeoxynucleotide delivery to the ocular surface.Mol Pharm 2011;8(6):2282-90.
[79]Yu S,Zhang X,Tan G,et al.A novel pH-induced thermosensitive hydrogel composed of carboxymethyl chitosan and poloxamer cross-linked by glutaraldehyde for ophthalmic drug delivery.Carbohydr Polym2017;155:208-17.
[80]Davaran S,Lotfipour F,Sedghipour N,Sedghipour MR,Alimohammadi S,Salehi R.Preparation and in vivo evaluation of in situ gel system as dual thermo-/pH-responsive nanocarriers for sustained ocular drug delivery.J Microencapsul 2015;32(5):511-19.
[81]Gupta H,Malik A,Khar RK,Ali A,Bhatnagar A,Mittal G.Physiologically active hydrogel(in situ gel)of sparfloxacin and its evaluation for ocular retention using gamma scintigraphy.J Pharm Bioallied Sci 2015;7(3):195-200.
[82]Gupta H,Velpandian T,Jain S.Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery.J Drug Target 2010;18(7):499-505.
[83]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retention.J Pharm Bioallied Sci2015;7(1):9-14.
[84]Basaran B,Bozkir A.Thermosensitive and p H induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride:hydroxypropyl-beta-cyclodextrin complex.Acta Pol Pharm 2012;69(6):1137-47.
[85]Pardeshi C,Rajput P,Belgamwar V,et al.Solid lipid based nanocarriers:an overview.Acta Pharm 2012;62(4):433-72.
[86]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.Nanomedicine 2010;6(2):324-33.
[87]Pitorre M,Gonde H,Haury C,et al.Recent advances in nanocarrier-loaded gels:which drug delivery technologies against which diseases?J Control Release 2017;266:140-55.
[88]Liu R,Sun L,Fang S,et al.Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin:development,characterization,in vitro permeation and in vivo pharmacokinetic studies.Pharm Dev Technol2016;21(5):576-82.
[89]Pandurangan DK,Bodagala P,Palanirajan VK,Govindaraj S.Formulation and evaluation of voriconazole ophthalmic solid lipid nanoparticles in situ gel.Int J Pharm Investig2016;6(1):56-62.
[90]Paradkar MU,Parmar M.Formulation development and evaluation of Natamycin niosomal in-situ gel for ophthalmic drug delivery.Journal of Drug Delivery Science&Technology 2017;39:113-22.
[91]Shukr MH.Novel in situ gelling ocular inserts for voriconazole-loaded niosomes:design,in vitro characterisation and in vivo evaluation of the ocular irritation and drug pharmacokinetics.J Microencapsul2016;33(1):71-9.
[92]Sayed EG,Hussein AK,Khaled KA,Ahmed OA.Improved corneal bioavailability of ofloxacin:biodegradable microsphere-loaded ion-activated in situ gel delivery system.Drug Des Devel Ther 2015;9:1427-35.
[93]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention.Drug Deliv 2013;20(7):306-9.
[94]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.Nanoparticles laden in situ gel for sustained ocular drug delivery.J Pharm Bioallied Sci 2013;5(2):162-5.
[95]Ahmed TA,Aljaeid BM.A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide)nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.Int J Nanomedicine2017;12:1863-75.
[96]Yu S,Wang Q,Wang X,et al.Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate.Int J Pharm 2015;480(1-2):128-36.
[97]Gan L,Gan Y,Zhu C,Zhang X,Zhu J.Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A:In vitro and in vivo results.In J Pharm 2009;365(1-2):143-9.
[98]Singh J,Chhabra G,Pathak K.Development of acetazolamide-loaded,pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery:in vitro.ex vivo evaluation and pharmacodynamic study.Drug Dev Ind Pharm 2014;40(9):1223-32.
[99]Ako-Adounvo AM,Nagarwal RC,Oliveira L,et al.Recent patents on ophthalmic nanoformulations and therapeutic implications.Recent Pat Drug Deliv Formul2014;8(3):193-201.
[100]Kant A,Reddy S,MM S,JS V,C N.In situ gelling system-An overview.Pharmacologyonline 2011;2(1):28-44.
[101]Jain D,Kumar V,Singh S,Mullertz A,Bar-Shalom D.Newer trends in in situ gelling systems for controlled ocular drug delivery.J Anal Pharm Res 2016;2(3):00022.
[102]Adeyeye MC,Davis VL,Kotreka UK.In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts.US 2011/0082128 A1.2011.
[103]Xia E,Smerbeck RV.Reversible gelling system for ocular drug delivery.US 2002/0114778 A1.2002.
[104]Banerjee R,Carvalho E.Nanoparticulate in-situ gels of TPGS,gellan and PVA as vitreous humor substitutes.US8,343,471 B2.2013.
[105]Chandavarkar NM,Jindal KC,Malayandi R.In-situ gel forming solution for ocular drug delivery.WO 2011018800A3.2011.
[106]Xia E,Smerbeck RV.Reversible gelling system for ocular drug delivery.US 6,703,039 B2.2004.
[107]Lin HR,Sung KC.Ophthalmic drug delivery formulations and method for preparing the same.US 6,511,660 B1.2003.
[2]Joseph RR,Venkatraman SS.Drug delivery to the eye:what benefits do nanocarriers offer.Nanomedicine(Lond)2017;12(6):683-702.
[3]Zhu M,Wang J,Li N.A novel thermo-sensitive hydrogel-based on poly(N-isopropylacrylamide)/hyaluronic acid of ketoconazole for ophthalmic delivery.Artif Cells Nanomed Biotechnol 2017.doi:10.1080/21691401.2017.1368024.
[4]Bisht R,Mandal A,Jaiswal JK,Rupenthal ID.Nanocarrier mediated retinal drug delivery:overcoming ocular barriers to treat posterior eye diseases.WIREs Nanomed Nanobiotechnol 2018.doi:10.1002/wnan.1473.
[5]Makwana SB,Patel VA,Parmar SJ.Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride.Results Pharma Sci2016;6:1-6.
[6]Kaur IP,Smitha R.Penetration enhancers and ocular bioadhesives:two new avenues for ophthalmic drug delivery.Drug Dev Ind Pharm 2002;28(4):353-69.
[7]Bamiro OA,Ubale RV,Addo RT.Background of Ocular Drug Delivery.In:Addo RT,editor.Ocular drug delivery:Advances,challenges and applications.Springer International Publishing;2016.p.1-9.
[8]Kotreka UK,Davis VL,Adeyeye MC.Development of topical ophthalmic in situ gel-forming estradiol delivery system intended for the prevention of age-related cataracts.PLoSOne 2017;12(2):e0172306.
[9]Ye T,Yuan K,Zhang W,et al.Prodrugs incorporated into nanotechnology-based drug delivery systems for possible improvement in bioavailability of ocular drugs delivery.Asian J Pharmaceut Sci 2013;8(4):207-17.
[10]Liu Y,Liu J,Zhang X,Zhang R,Huang Y,Wu C.In situ gelling gelrite/alginate formulations as vehicles for ophthalmic drug delivery.AAPS PharmSciTech 2010;11(2):610-20.
[11]Tan G,Yu S,Pan H,et al.Bioadhesive chitosan-loaded liposomes:a more efficient and higher permeable ocular delivery platform for timolol maleate.Int J Biol Macromol2017;94(Pt A):355-63.
[12]Addo RT,Yeboah KG,Siwale RC,et al.Formulation and characterization of atropine sulfate in albumin-chitosan microparticles for in vivo ocular drug delivery.J Pharm Sci2015;104(5):1677-90.
[13]Biswas GR,Majee SB.Niosomes in ocular drug delivery.Eur JPharmaceut Med Res 2017;4(7):813-19.
[14]Prausnitz MR,Jiang J,Pate SR,et al..In:Ocular drug delivery using microneedles;2007.p.3191.
[15]Duan Y,Cai X,Du H,Zhai G.Novel in situ gel systems based on P123/TPGS mixed micelles and gellan gum for ophthalmic delivery of curcumin.Colloids Surf BBiointerfaces 2015;128:322-30.
[16]Malavade S.Overview of the ophthalmic system.In:Pathak Y,Sutariya V,Hirani AA,editors.Nano-Biomaterials for ophthalmic drug delivery.Springer International Publishing;2016.p.9-35.
[17]Almeida H,Amaral MH,Lobao P,Lobo JM.In situ gelling systems:a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations.Drug Discov Today 2014;19(4):400-12.
[18]Weng Y,Liu J,Jin S,Guo W,Liang X,Hu Z.Nanotechnology-based strategies for treatment of ocular disease.Acta Pharm Sin B 2017;7(3):281-91.
[19]Huang D,Chen YS,Rupenthal ID.Overcoming ocular drug delivery barriers through the use of physical forces.Adv Drug Deliv Rev 2017.doi:10.1016/j.addr.2017.09.008.
[20]Achouri D,Alhanout K,Piccerelle P,Andrieu V.Recent advances in ocular drug delivery.Drug Dev Ind Pharm2013;39(11):1599-617.
[21]Khan N,Aqil M,Imam SS,Ali A.Development and evaluation of a novel in situ gel of sparfloxacin for sustained ocular drug delivery:in vitro and ex vivo characterization.Pharm Dev Technol 2015;20(6):662-9.
[22]Li J,Zhao H,Okeke CI,et al.Comparison of systemic absorption between ofloxacin ophthalmic in situ gels and ofloxacin conventional ophthalmic solutions administration to rabbit eyes by HPLC-MS/MS.Int J Pharm2013;450(1-2):104-13.
[23]Devasani SR,Dev A,Rathod S,Deshmukh G.An overview of in situ gelling systems.Pharmaceut Biolog Evaluat2016;3(1):60-9.
[24]Cao Y,Zhang C,Shen W,Cheng Z,Yu LL,Ping Q.Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.J Control Release 2007;120(3):186-94.
[25]Sheshala R,Kok YY,Ng JM,Thakur RR,Dua K.In situ gelling ophthalmic drug delivery system:an overview and its applications.Recent Pat Drug Deliv Formul 2015;9(3):237-48.
[26]Laddha UD,Mahajan HS.An insight to ocular in situ gelling systems.Int J Adv Pharmaceut 2017;06(02):31-40.
[27]Wei G,Xu H,Ding PT,Li SM,Zheng JM.Thermosetting gels with modulated gelation temperature for ophthalmic use:the rheological and gamma scintigraphic studies.J Control Release 2002;83(1):65-74.
[28]Patel N,Nakrani H,Raval M,Navin S.Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.Drug Deliv 2016;23(9):3712-23.
[29]Klouda L.Thermoresponsive hydrogels in biomedical applications:a seven-year update.Eur J Pharm Biopharm2015;97(Pt B):338-49.
[30]Almeida H,Amaral MH,Lobao P.Temperature and p Hstimuli-responsive polymers and their applications in controlled and selfregulated drug delivery.J App Pharm Sci2012;2(6):1-10.
[31]Almeida H,Amaral MH,Lobao P,Sousa Lobo JM.Applications of poloxamers in ophthalmic pharmaceutical formulations:an overview.Expert Opin Drug Deliv2013;10(9):1223-37.
[32]Escobar-Chavez JJ,Lopez-Cervantes M,Naik A,Kalia YN,Quintanar-Guerrero D,Ganem-Quintanar A.Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations.J Pharm Pharm Sci 2006;9(3):339-58.
[33]Miyazaki S,Suzuki S,Kawasaki N,Endo K,Takahashi A,Attwood D.In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride.Int J Pharm 2001;229(1):29-36.
[34]Zambito Y,Colo GD.Polysaccharides as excipients for ocular topical formulations.Polysaccharides as excipients for ocular topical formulations.In Tech;2011.p.253-80.
[35]Rajoria G,Gupta A.In-situ gelling system:a novel approach for ocular drug delivery.Am J PharmTech Res2012;2(4):24-53.
[36]Pal K,Paulson AT,Rousseau D.Biopolymers in controlled-release delivery systems.In:Ebnesajjad S,editor.Handbook of biopolymers and biodegradable plastics properties,processing,and applications.Elsevier;2013.p.347-8.
[37]Mohammed S,Chouhan G,Anuforom O,et al.Thermosensitive hydrogel as an in situ gelling antimicrobial ocular dressing.Mater Sci Eng C Mater Biol Appl 2017;78:203-9.
[38]Liu L,Gao Q,Lu X,Zhou H.In situ forming hydrogels based on chitosan for drug delivery and tissue regeneration.Asian J Pharmaceut Sci 2016;11(6):673-83.
[39]Chen X,Li X,Zhou Y,et al.Chitosan-based thermosensitive hydrogel as a promising ocular drug delivery system:preparation,characterization,and in vivo evaluation.JBiomater Appl 2012;27(4):391-402.
[40]Shastri DH.Thiolated chitosan:a boon to ocular delivery of therapeutics.MOJ Bioequiv Availab 2017;3(2):1-5.
[41]Li J,Liu H,Liu LL,Cai CN,Xin HX,Liu W.Design and evaluation of a Brinzolamide drug-resin in situ thermosensitive gelling system for sustained ophthalmic drug delivery.Chem Pharm Bull(Tokyo)2014;62(10):1000-1008.
[42]Al-Khateb K,Ozhmukhametova EK,Mussin MN,et al.In situ gelling systems based on Pluronic F127/Pluronic F68formulations for ocular drug delivery.Int J Pharm2016;502(1-2):70-9.
[43]Osswald CR,Guthrie MJ,Avila A,Valio JJ,Mieler WF,Kang-Mieler JJ.In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system.Curr Eye Res 2017;42(9):1293-301.
[44]Vodithala S,Khatry S,Shastri N,Sadanandam M.Development and evaluation of thermoreversible ocular gels of ketorolac tromethamine.Int J Biopharm2010;1(1):39-45.
[45]Morsi N,Ghorab D,Refai H,Teba H.Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery.Int J Pharm 2016;506(1-2):57-67.
[46]Bhowmik M,Bain MK,Ghosh LK,Chattopadhyay D.Effect of salts on gelation and drug release profiles of methylcellulose-based ophthalmic thermo-reversible in situ gels.Pharm Dev Technol 2011;16(4):385-91.
[47]Bhowmick B,Sarkar G,Roy I,et al.Effect of carrageenan and potassium chloride on in-situ gelling ophthalmic drug delivery system based on methylcellulose.Rsc Adv2015;5(74):60386-91.
[48]Gratieri T,Gelfuso GM,Rocha EM,Sarmento VH,de-Freitas O,Lopez RF.A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery.Eur J Pharm Biopharm 2010;75(2):186-93.
[49]Hsiue GH,Hsu SH,Yang CC,Lee SH,Yang IK.Preparation of controlled release ophthalmic drops,for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide.Biomaterials 2002;23(2):457-62.
[50]Iohara D,Okubo M,Anraku M,et al.Hydrophobically modified polymer/α-cyclodextrin thermoresponsive hydrogels for use in ocular drug delivery.Mol Pharm2017;14(8):2740-8.
[51]Sawant D,Dandagi PM,Gadad AP.Formulation and evaluation of sparfloxacin emulsomes-loaded thermosensitive in situ gel for ophthalmic delivery.JSol-Gel Sci Technol 2016;77(3):654-65.
[52]Wang L,Che X,Guo Y,Bian Y,Cheng G.Thermoresponsive ophthalmic poloxamer/tween/carbopol in situ gels of a poorly water-soluble drug fluconazole:preparation and in vitro-in vivo evaluation.Drug Dev Ind Pharm2014;40(10):1402-10.
[53]Gadad AP,Wadklar PD,Dandghi P,Patil A.Thermosensitive in situ gel for ocular delivery of lomefloxacin.Ind JPharmaceut Educ Res 2016;50(2):S96-105.
[54]Qian Y,Wang F,Li R,Zhang Q,Xu Q.Preparation and evaluation of in situ gelling ophthalmic drug delivery system for methazolamide.Drug Dev Ind Pharm2010;36(11):1340-7.
[55]Asasutjarit R,Thanasanchokpibull S,Fuongfuchat A,Veeranondha S.Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels.Int J Pharm 2011;411(1-2):128-35.
[56]Ammar HO,Salama HA,Ghorab M,Mahmoud AA.Development of dorzolamide hydrochloride in situ gel nanoemulsion for ocular delivery.Drug Dev Ind Pharm2010;36(11):1330-9.
[57]Lin HR,Sung KC.Carbopol/pluronic phase change solutions for ophthalmic drug delivery.J Control Release2000;69(3):379-88.
[58]Wu H,Liu Z,Peng J,Li L,Li N,Li J.Design and evaluation of baicalin-containing in situ pH-triggered gelling system for sustained ophthalmic drug delivery.Int J Pharm2011;410(1-2):31-40.
[59]Pang X,Li J,Pi J,et al.Increasing efficacy and reducing systemic absorption of brimonidine tartrate ophthalmic gels in rabbits.Pharm Dev Technol 2018;23(3):231-9.
[60]Upadhayay P,Kumar M,Pathak K.Norfloxacin loaded p Htriggered nanoparticulate in-situ gel for extraocular bacterial infections:optimization,ocular irritancy and corneal toxicity.Iran J Pharm Res 2016;15(1):3-22.
[61]Gupta S,Vyas SP.Carbopol/chitosan based p H triggered in situ gelling system for ocular delivery of timolol maleate.Sci Pharm 2010;78(4):959-76.
[62]Kanoujia J,Sonker K,Pandey M,Kymonil KM,Saraf SA.Formulation and characterization of a novel pH-triggered in-situ gelling ocular system containing Gatifloxacin.Int Current Pharmaceut J 2012;1(3):43-9.
[63]Sheikh AA,Sheikh SR,Admane SS.Development and characterization of novel in situ gel of moxifloxacin hydrochloride.Asian J.Pharm.2017;11(3):S616-24.
[64]Rupenthal ID,Green CR,Alany RG.Comparison of ion-activated in situ gelling systems for ocular drug delivery.part 2:precorneal retention and in vivo pharmacodynamic study.Int J Pharm 2011;411(1-2):78-85.
[65]Agrawal AK,Das M,Jain S.In situ gel systems as’smart’carriers for sustained ocular drug delivery.Expert Opin Drug Deliv 2012;9(4):383-402.
[66]Fernandez-Ferreiro A,Fernandez Bargiela N,Varela MS,et al.Cyclodextrin-polysaccharide-based,in situ-gelled system for ocular antifungal delivery.Beilstein J Org Chem2014;10:2903-11.
[67]Reed K,Li A,Wilson B,Assamoi T.Enhancement of ocular in situ gelling properties of low acyl gellan gum by use of ion exchange.J Ocul Pharmacol Ther 2016;32(9):574-82.
[68]Champalal KD,Sushilkumar SP.Current status of ophthalmic in-situ forming hydrogel.Int J Pharma Bio Sci2012;3(3):P372-88.
[69]Mishra DN,Gilhotra RM.Design and characterization of bioadhesive in-situ gelling ocular inserts of Gatifloxacin sesquihydrate.DARU:J Pharmaceut Sci 2008;16(1):1-8.
[70]Nirmal HB,Bakliwal SR,Pawar SP.In-situ gel:new trends in controlled and sustained drug delivery system.Int JPharmTech Res 2010;2(2):1398-408.
[71]Vijaya C,Goud KS.Ion-activated in situ gelling ophthalmic delivery systems of Azithromycin.Indian J of Pharm Sci2011;73(6):615-20.
[72]Zhu L,Ao J,Li P.A novel in situ gel base of deacetylase gellan gum for sustained ophthalmic drug delivery of ketotifen:in vitro and in vivo evaluation.Drug Des Devel Ther 2015;9:3943-9.
[73]Kesarla R,Tank T,Vora PA,Shah T,Parmar S,Omri A.Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel.Drug Deliv 2016;23(7):2363-70.
[74]Tayel SA,El-Nabarawi MA,Tadros MI,Abd-Elsalam WH.Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride:design,in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits.Int JPharm 2013;443(1-2):293-305.
[75]Liu Z,Li J,Nie S,Liu H,Ding P,Pan W.Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin.Int J Pharm 2006;315(1-2):12-17.
[76]Liu Z,Yang XG,Li X,Pan W,Li J.Study on the ocular pharmacokinetics of ion-activated in situ gelling ophthalmic delivery system for gatifloxacin by microdialysis.Drug Dev Ind Pharm 2007;33(12):1327-31.
[77]Morsi N,Ibrahim M,Refai H,El Sorogy H.Nanoemulsion-based electrolyte triggered in situ gel for ocular delivery of acetazolamide.Eur J Pharm Sci2017;104:302-14.
[78]Rupenthal ID,Alany RG,Green CR.Ion-activated in situ gelling systems for antisense oligodeoxynucleotide delivery to the ocular surface.Mol Pharm 2011;8(6):2282-90.
[79]Yu S,Zhang X,Tan G,et al.A novel pH-induced thermosensitive hydrogel composed of carboxymethyl chitosan and poloxamer cross-linked by glutaraldehyde for ophthalmic drug delivery.Carbohydr Polym2017;155:208-17.
[80]Davaran S,Lotfipour F,Sedghipour N,Sedghipour MR,Alimohammadi S,Salehi R.Preparation and in vivo evaluation of in situ gel system as dual thermo-/pH-responsive nanocarriers for sustained ocular drug delivery.J Microencapsul 2015;32(5):511-19.
[81]Gupta H,Malik A,Khar RK,Ali A,Bhatnagar A,Mittal G.Physiologically active hydrogel(in situ gel)of sparfloxacin and its evaluation for ocular retention using gamma scintigraphy.J Pharm Bioallied Sci 2015;7(3):195-200.
[82]Gupta H,Velpandian T,Jain S.Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery.J Drug Target 2010;18(7):499-505.
[83]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retention.J Pharm Bioallied Sci2015;7(1):9-14.
[84]Basaran B,Bozkir A.Thermosensitive and p H induced in situ ophthalmic gelling system for ciprofloxacin hydrochloride:hydroxypropyl-beta-cyclodextrin complex.Acta Pol Pharm 2012;69(6):1137-47.
[85]Pardeshi C,Rajput P,Belgamwar V,et al.Solid lipid based nanocarriers:an overview.Acta Pharm 2012;62(4):433-72.
[86]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery.Nanomedicine 2010;6(2):324-33.
[87]Pitorre M,Gonde H,Haury C,et al.Recent advances in nanocarrier-loaded gels:which drug delivery technologies against which diseases?J Control Release 2017;266:140-55.
[88]Liu R,Sun L,Fang S,et al.Thermosensitive in situ nanogel as ophthalmic delivery system of curcumin:development,characterization,in vitro permeation and in vivo pharmacokinetic studies.Pharm Dev Technol2016;21(5):576-82.
[89]Pandurangan DK,Bodagala P,Palanirajan VK,Govindaraj S.Formulation and evaluation of voriconazole ophthalmic solid lipid nanoparticles in situ gel.Int J Pharm Investig2016;6(1):56-62.
[90]Paradkar MU,Parmar M.Formulation development and evaluation of Natamycin niosomal in-situ gel for ophthalmic drug delivery.Journal of Drug Delivery Science&Technology 2017;39:113-22.
[91]Shukr MH.Novel in situ gelling ocular inserts for voriconazole-loaded niosomes:design,in vitro characterisation and in vivo evaluation of the ocular irritation and drug pharmacokinetics.J Microencapsul2016;33(1):71-9.
[92]Sayed EG,Hussein AK,Khaled KA,Ahmed OA.Improved corneal bioavailability of ofloxacin:biodegradable microsphere-loaded ion-activated in situ gel delivery system.Drug Des Devel Ther 2015;9:1427-35.
[93]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention.Drug Deliv 2013;20(7):306-9.
[94]Gupta H,Aqil M,Khar RK,Ali A,Bhatnagar A,Mittal G.Nanoparticles laden in situ gel for sustained ocular drug delivery.J Pharm Bioallied Sci 2013;5(2):162-5.
[95]Ahmed TA,Aljaeid BM.A potential in situ gel formulation loaded with novel fabricated poly(lactide-co-glycolide)nanoparticles for enhancing and sustaining the ophthalmic delivery of ketoconazole.Int J Nanomedicine2017;12:1863-75.
[96]Yu S,Wang Q,Wang X,et al.Liposome incorporated ion sensitive in situ gels for opthalmic delivery of timolol maleate.Int J Pharm 2015;480(1-2):128-36.
[97]Gan L,Gan Y,Zhu C,Zhang X,Zhu J.Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A:In vitro and in vivo results.In J Pharm 2009;365(1-2):143-9.
[98]Singh J,Chhabra G,Pathak K.Development of acetazolamide-loaded,pH-triggered polymeric nanoparticulate in situ gel for sustained ocular delivery:in vitro.ex vivo evaluation and pharmacodynamic study.Drug Dev Ind Pharm 2014;40(9):1223-32.
[99]Ako-Adounvo AM,Nagarwal RC,Oliveira L,et al.Recent patents on ophthalmic nanoformulations and therapeutic implications.Recent Pat Drug Deliv Formul2014;8(3):193-201.
[100]Kant A,Reddy S,MM S,JS V,C N.In situ gelling system-An overview.Pharmacologyonline 2011;2(1):28-44.
[101]Jain D,Kumar V,Singh S,Mullertz A,Bar-Shalom D.Newer trends in in situ gelling systems for controlled ocular drug delivery.J Anal Pharm Res 2016;2(3):00022.
[102]Adeyeye MC,Davis VL,Kotreka UK.In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts.US 2011/0082128 A1.2011.
[103]Xia E,Smerbeck RV.Reversible gelling system for ocular drug delivery.US 2002/0114778 A1.2002.
[104]Banerjee R,Carvalho E.Nanoparticulate in-situ gels of TPGS,gellan and PVA as vitreous humor substitutes.US8,343,471 B2.2013.
[105]Chandavarkar NM,Jindal KC,Malayandi R.In-situ gel forming solution for ocular drug delivery.WO 2011018800A3.2011.
[106]Xia E,Smerbeck RV.Reversible gelling system for ocular drug delivery.US 6,703,039 B2.2004.
[107]Lin HR,Sung KC.Ophthalmic drug delivery formulations and method for preparing the same.US 6,511,660 B1.2003.